Cargando…
Role of Biomarkers in FLT3 AML
SIMPLE SUMMARY: Genetically heterogeneous disorder acute myeloid leukemia (AML) is marked by recurring mutations in FLT3. Current FLT3 inhibitors and other emerging inhibitors have helped in the improvement of the quality of standard of care therapies; however, the overall survival of the patients r...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909069/ https://www.ncbi.nlm.nih.gov/pubmed/35267471 http://dx.doi.org/10.3390/cancers14051164 |